The negative impact of vitamin D on antipsychotic drug exposure may counteract its potential benefits in schizophrenia.

Arnim Johannes GaeblerMichelle Finner-PrévelSarah LammertzSabrina SchaffrathPatrick EisnerFelix StöhrErik RöcherLina WinklerPeter KaletaLaura LenzenMarc AugustinJana HovancakovaLara SchwemmerEva StormannsFatih KeskinFrederik HendricksMichael PaulzenGerhard GründerFrank Schneidernull nullKlaus Mathiak

Published in: British journal of clinical pharmacology (2022)

Despite vitamin D's potential benefits on physical and mental health, clinicians should be aware of its negative impact on blood concentrations of antipsychotics metabolized by CYP3A4 in patients with schizophrenia. Therefore, when considering its supplementation, therapeutic drug monitoring should be applied to guide dose adjustment.

Keyphrases

mental health
bipolar disorder
palliative care
mental illness
emergency department
drug induced
adverse drug
risk assessment
climate change